Language
中文
繁體
EN
About
Overview
Team
History
Branch
Honor
Culture
Science&Products
R & D Platform
Product pipeline
Product Introduction
Patient
Previous research
Patient Recruitment
Blog
Company News
Industry news
Investor
Prospectus
Financial report
Announcement and Circular
Corporate Governance
Investor Inquiry
Cooperation
Careers
Talent Strategy
Social Recruitment
Campus Recruitment
Contact
Message
English
español
Русский
Patient Area
The commercialization process of CAR-T therapy in China is accelerating, and Immunotech Biopharm Biotech has completed the enrollment of its first patient.
2021-06-27
New Hope for Ovarian Cancer: Immunotech Biopharm Biotech's Clinical Progress on 6B11
2021-07-12
Immunotech Biopharm (06978) has received strategic investment from China Resources Pharmaceutical, accelerating the release of its intrinsic value.
2021-07-22
Public Participation Information Announcement for the Environmental Impact Assessment of the New Tumor Product - Immunocellular Product Industrialization Project
2021-08-09
Immunotech Biopharm partners with SAP to create a digital operation management platform to combat tumors with digital power.
2021-08-20
Immunotech Biopharm Biotech has reached a strategic cooperation with China Resources Pharmaceutical to jointly promote commercialization.
2021-09-18
New Tumor Product - Immunocellular Product Industrialization Project Environmental Impact Assessment First Public Participation Information Announcement
2021-10-08
Immunotech Biopharm (06978.HK) made its presence known in Wuzhong, making a significant appearance at the first Taihu Pharmaceutical Innovation Conference.
2021-10-22
Immunotech Biopharm | The National Health Commission issued a notice on the "Action Plan for Improving the Quality of Cancer Diagnosis and Treatment"; Singapore's Baijie (China) biopharmaceutical production base has been established.
2021-10-25
Major Award | Immunotech Biopharm won the 2021 Deloitte Beijing E-Town Star
2021-11-01
